Axonics has achieved FDA approval for its recharge-free sacral neuromodulation (SNM) implantable neurostimulator, the Axonics F15. This device boasts a functional life exceeding 15 years at standard stimulation parameters and 20 years at lower settings. It is 20% smaller than competitors, features full-body MRI compatibility, and an intuitive patient remote control. The company plans to launch a national advertising campaign to boost awareness for SNM therapy, which addresses incontinence affecting millions of Americans. The shipping is set to commence in April.
Axonics, Inc. (Nasdaq: AXNX) reported a 53% increase in fourth-quarter revenue to $53.1 million year-over-year, driven by strong sales in sacral neuromodulation (SNM) and Bulkamid products. For fiscal year 2021, revenue reached $180.3 million, marking a 62% year-over-year growth. However, the company posted a net loss of $80.1 million for FY 2021, compared to $54.9 million in FY 2020. Looking ahead, Axonics projects 2022 revenue of $234 million, a 30% increase, with SNM and Bulkamid anticipated to grow by 25% and 63%, respectively.
Axonics, Inc. (NASDAQ: AXNX) will announce its fourth quarter and fiscal year 2021 financial results on February 24, 2022, after market close. A conference call to discuss these results will take place at 4:30 p.m. Eastern Time, accessible via call or webcast. Axonics, recognized as the fastest-growing medical technology company by Deloitte’s 2021 Technology Fast 500™, develops innovative treatments for bladder and bowel dysfunction. Their rechargeable sacral neuromodulation system effectively addresses overactive bladder and fecal incontinence, while Bulkamid offers durable relief for stress urinary incontinence.
Axonics, a medical technology company based in Irvine, California, will participate in the SVB Leerink Virtual Healthcare Conference on February 17, 2022, at 12:00 p.m. Eastern Time. The presentation will be accessible through the Axonics investor relations website. The company is recognized for developing innovative treatments for bladder and bowel dysfunction, notably its rechargeable sacral neuromodulation system and Bulkamid, a urethral bulking agent. Axonics ranked No. 1 on the 2021 Deloitte Technology Fast 500, underscoring its rapid growth in the healthcare sector.
Axonics, Inc. (NASDAQ: AXNX) reports new findings on urinary incontinence (UI) prevalence in U.S. women, highlighting a surge to approximately 62%, affecting over 78 million women. This data, published in a peer-reviewed journal, shows a significant rise from earlier estimates (38%-53%). Factors like aging and obesity contribute to this increase. The company emphasizes the importance of routine UI screening and plans to launch a national advertising campaign to raise awareness about its treatments, including the rechargeable sacral neuromodulation system.
Axonics, Inc. (NASDAQ: AXNX) reported record quarterly revenue exceeding $50 million for the first time, with 4Q21 net revenue estimated between $52.9 and $53.3 million, a 53% increase year-over-year from $34.8 million. For fiscal year 2021, total company revenue is projected between $180.1 and $180.5 million, marking a 62% growth from $111.5 million in 2020. The company anticipates launching its recharge-free sacral neuromodulation system in 2022, signaling potential market leadership.
Axonics, a medical technology company, announced that CEO Raymond W. Cohen received the 2021 Lifetime Entrepreneurial Achievement Award from the Southern California Biomedical Council. This award highlights Cohen's contributions to the bioscience sector, including innovation and job creation. Axonics develops products for bladder and bowel dysfunction and manufactures locally in Irvine, California. The company addresses significant health issues affecting millions, including overactive bladder and fecal incontinence, and boasts established reimbursement coverage in the U.S. and Europe.
Axonics, Inc. (Nasdaq: AXNX) has been recognized as the fastest-growing company in the 2021 Deloitte Technology Fast 500, highlighting a staggering 87,037% revenue growth over three years. The company reported $111.5 million in revenue for FY 2020, up from $128,000 in FY 2017. CEO Raymond W. Cohen attributed this success to Axonics' mission-driven culture and continuous innovation in developing solutions for bladder and bowel dysfunction.
The Deloitte Fast 500 ranks companies based on fiscal year revenue growth, emphasizing their ability to adapt and thrive.
On November 17, 2021, Deloitte announced the North America Technology Fast 500, highlighting the fastest-growing tech companies from 2017 to 2020. Axonics, Inc. topped the list with an extraordinary growth rate of 87,037%. This ranking showcases a diverse array of sectors, with medical devices and software leading the charge. Overall, the Fast 500 companies exhibited impressive revenue growth, with a median increase of 521%. California's Silicon Valley remains a hub, contributing significantly to the rankings.
Axonics, Inc. (Nasdaq: AXNX), a medical technology company, will participate in the Piper Sandler Virtual Healthcare Conference on December 1, 2021. A pre-recorded fireside chat featuring Axonics senior management will be available on November 22, 2021, at 10:00 AM ET. Axonics specializes in innovative treatments for bladder and bowel dysfunction, with its rechargeable sacral neuromodulation system and the Bulkamid® urethral bulking agent. The company’s products are widely offered in the U.S. and Europe, providing solutions for millions affected by these conditions.